Journal article icon

Journal article

Luspatercept in patients with lower-risk myelodysplastic syndromes

Abstract:

Background:
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study.


Methods:
In a double-blind, placebo-controlled, phase 3 ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/nejmoa1908892

Authors


Expand authors...
Medical Research Council More from this funder
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
382
Pages:
140-151
Publication date:
2020-01-09
Acceptance date:
2019-12-19
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Pmid:
31914241
Language:
English
Keywords:
Pubs id:
1081784
Local pid:
pubs:1081784
Deposit date:
2020-06-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP